Annual Report 2006 - Boehringer Ingelheim

More documents

Recommendations

Info

Mothers deliver healthy babies Interview with Dr Charles Wanyonyi What is the situation in your area in terms of the HIV infection rate? The rate of HIV-infected people has gone down from 13 % in 2003 to at the moment 8 - 9 % of Kenya’s population. This drop is showing that the rate is now stabilising and is being brought under control. How long have you been using nevirapine at your hospital? We introduced a prevention of mother-to-child transmission programme in 2003, the aim of which was to inform HIV- positive expectant mothers about how to protect a baby from contracting the virus. They are also told of the importance of using nevirapine and we have been using it since then. How many mother-child pairs have been treated with nevirapine so far? Since we started the programme, we have handled approximately 4,500 cases. What is your opinion of nevirapine in terms of its efficacy and safety? Nevirapine is very effective and has helped many HIV-positive mothers deliver healthy babies. I must say that there has been a drastic drop of mother-to-child transmission during delivery. I have seen the drug work in a baby whose blood had been in contact with the virus during birth and where a dose of nevirapine had been given, which had then caused the virus to be wiped out and the antibodies to disappear. our caring culture Consultant obstetrician and gynaecologist Dr Charles Wanyonyi is Medical Director of Pumwani Maternity Hospital (PMH), the largest maternity institution in the East and Central Africa region. Located in Nairobi, the Kenyan capital, it is the most active site in Kenya for preventing mother-to-child transmission (PMTCT) of HIV. Dr Wanyonyi oversees the day to day running of PMH which provides antenatal, delivery and postnatal services, midwife training, research activities and healthcare programmes, such as PMTCT. VIRAMUNE® Donation Programme 1
1 Our people In pursuing our vision to create “Value through Innovation”, we build on the inspiration, expertise and dedication of our more than 38,400 people around the world. Their striving for continuous innovation and discovery of novel solutions enable us to maintain our growth, to sustain high-level performance and prepare for future challenges. Supported by our Leitbild (guiding principles) and our long-term strategic direction, we continue to focus on core issues for enhancing our people’s capabilities and their passion to pursue our vision everywhere we operate. A key element of our sustained success at Boehringer Ingelheim is the way we work together. Guided by fundamental questions contained in Lead & Learn, our common cultural understanding, we are individually and collectively called on to shape an environment where creativity, challenge, team-spirit, respect and fairness flourish. Interdisciplinary teams throughout our organisations continue to support this aspiration with unconventional and inspirational ways of questioning, sharing and learning from each other. Preferred employer recognition The strength of our distinctive working culture is winning wide acknowledgement from prestigious, independent workplace surveys (see page 17). We regard these awards as an affirma- tion of our success in establishing a demanding yet highly attractive working environment. The Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 6 surveys increasingly place us among the most preferred employers, giving us a competitive advantage in recruiting and retaining the best talent. In 2006, Boehringer Ingelheim was listed No. 2 among the top 20 employers of scientists in a respected survey among researchers in the USA and Europe (see page 15). Preparing for the future To ensure our sustained, positive development, a number of our organisations devoted substantial attention in 2006 to capitalising on opportunities to improve business and operating efficiency beyond existing continuous improvement. Hence, processes have been launched in which our employees have contributed powerful insights into how we can reinvent ourselves, create structures and processes for better serving the marketplace, reducing costs and redundancies, as well as working more efficiently and securing breakthroughs.
Page 1 and 2: Value through Innovation Annual Rep
Page 3 and 4: Contents 1 Value Through Innovation
Page 5 and 6: The Shareholders’ Perspective Dea
Page 7 and 8: Key Aspects of 2006 2006 was again
Page 9 and 10: This growth was clearly restrained
Page 11 and 12: Shareholders’ Committee Dr Heribe
Page 13 and 14: “There is help” “The woman wh
Page 15: 1 continued from page 10 A Kenyan m
Page 19 and 20: Company childcare enters new territ
Page 21 and 22: 1 Caring for our neighbours We are
Page 23 and 24: 0 Children from St Margaret Clither
Page 25 and 26: Our environment & employee safety A
Page 27 and 28: thanks to the use of the wood-fired
Page 29 and 30: Our goals We shall continue to inve
Page 31 and 32: Targeting tomorrow’s therapies Th
Page 33 and 34: 0 continued from page 28 “Boehrin
Page 35 and 36: Our R & D strategy Research and dev
Page 37 and 38: Ridgefield, USA Cardiovascular, imm
Page 39 and 40: Vienna, Austria Oncology Boehringer
Page 41 and 42: Our expertise in landmark studies L
Page 43 and 44: From mind to man - the R & D proces
Page 45 and 46: New biological entities (NBE) One o
Page 47 and 48: The development of our businesses W
Page 49: Rin Fujima, Kyoto, Japan, suffers f
Page 52 and 53: Human Pharmaceuticals Branded presc
Page 54 and 55: cal exercise capacity and the reduc
Page 56 and 57: “Like a great round of golf“
Page 58 and 59: gives patients a better chance of g
Page 60 and 61: aptivus® was launched in the USA i
Page 62 and 63: enzymes, such as the HCV serine pro
Page 64 and 65: Børge Madsen, Copenhagen, Denmark.
Page 66 and 67:
Cardiovascular diseases Despite sig
Page 68 and 69:
actilyse® is the first and only th
Page 70 and 71:
fibrillation in some 40 countries i
Page 72 and 73:
Treatment modalities used to reliev
Page 74 and 75:
HuCAL antibody directed against a c
Page 76 and 77:
hand, the end of exclusivity in Eur
Page 78 and 79:
Generic Prescription Medicines The
Page 80 and 81:
Ben Venue - a world leader in steri
Page 82 and 83:
Mara Lovera, Buenos Aires, Argentin
Page 84 and 85:
Consumer Health Care Our Consumer H
Page 86 and 87:
Switching reinforces the trend towa
Page 88 and 89:
Alexander (left) and Christopher pl
Page 90 and 91:
Animal Health The sound progress of
Page 92 and 93:
located, trained and placed with fi
Page 94 and 95:
Our Customer Orientation Our custom
Page 96 and 97:
On a biopharmaceutical compound’s
Page 98 and 99:
Pharmaceuticals Production Our Phar
Page 100 and 101:
Counterfeits - a real threat for pa
Page 102 and 103:
Group Management Report 2006
Page 104 and 105:
companies lost their patent protect
Page 106 and 107:
To summarise, we see the success of
Page 108 and 109:
Production Production sites belongi
Page 110 and 111:
In the area of HIV/AIDS therapy, we
Page 112 and 113:
only 2 %. The region’s overall ne
Page 114 and 115:
of the cash flow, which rose by EUR
Page 116 and 117:
Report on expected developments The
Page 118 and 119:
Consolidated Financial Statements 2
Page 120 and 121:
C. H. Boehringer Sohn Grundstücksv
Page 122 and 123:
C. H. Boehringer Sohn, Ingelheim Co
Page 124 and 125:
C. H. Boehringer Sohn, Ingelheim St
Page 126 and 127:
The following subsidiaries were exe
Page 128 and 129:
2 Accounting and evaluation methods
Page 130 and 131:
3 Notes to the consolidated balance
Page 132 and 133:
3.3 Financial assets (in millions o
Page 134 and 135:
Pension provisions Boehringer Ingel
Page 136 and 137:
4 Notes to the consolidated profit
Page 138 and 139:
4.7 Holding income (in millions of
Page 140 and 141:
Other mandatory disclosures accordi
Page 142 and 143:
Derivative financial instruments at
Page 144 and 145:
With the following exception, our a
Page 146 and 147:
Product name Active ingredient Indi
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2006 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?